Trials / Completed
CompletedNCT00543634
Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women
Open-Label, Single-Dose, Partially Randomized, 6-Period, 6-Treatment, Crossover Bioavailability Study of 3 Pilot Formulations of Premarin®/Medroxyprogesterone Acetate (MPA) Compared With Reference Formulations of Premarin®/MPA (PREMPRO®) and MPA Suspension (Provera®) in Healthy Postmenopausal Women
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 35 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the safety and efficacy of new tablet formulations of Premarin®/medroxyprogesterone (MPA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Premarin/MPA | 0.625 mg/2.5 mg X4 |
| DRUG | Premarin/MPA | 0.625 mg/5 mg X 2 |
| DRUG | Provera 10 mg | 2.5 mg of MPA, 4 tablets dissoved in water |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2007-10-15
- Last updated
- 2010-06-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00543634. Inclusion in this directory is not an endorsement.